Senate Expands Infant Formula Safety, Supply Workload For FDA, Industry In User Fees Bill
Executive Summary
HELP Committee passes five-year reauthorization of FDA drug, medical device and biosimilar user fees with separate provisions expanding agency’s authority to regulate infant formula manufacturing and marketing and establishing Office of Critical Foods in CFSAN.
You may also be interested in...
External Evaluation For US FDA Food Safety ‘Structure, Function, Funding and Leadership’
Members of Congress won’t find mention of criticism of FDA food safety oversight linked most recently to infant formula shortage in Commissioner Califf's announcement. He also didn’t refer to the formula shortage.
House Appropriators Reject Docking FDA FY2023 Budget Until Formula Crisis Report Provided
First-term Iowa Republican Hinson had support from Democrat as well as other GOP members for withholding part of commissioner office’s FY2023 budget. Opposition from a self-acknowledged unlikely source, committee chair DeLauro, steered votes toward rejecting the proposal.
US Bill To Radically Overhaul Cosmetics Regulations Passes Senate HELP Committee
One voice emerged from the committee markup session as a potential cosmetics industry ally. In his opening remarks, ranking member Richard Burr, R-NC, said, “I worry that we’re rewarding bad behavior. Is this the time to expand FDA authority in any space, including diagnostic tests, cosmetics, and dietary supplements?”